ESH MM 2018 | MRD sequencing test approved for MM in the US

Nikhil Munshi

Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the prospects for measurable residual disease (MRD) testing following the recent FDA approval of a deep sequencing-based technique for MRD detection in multiple myeloma (MM). This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video